Evidera, an evidence-based solution provider, is the peri- and post-approval business unit of the global contract research organization (CRO) Pharmaceutical Product Development, LLC (PPD).
PDD completed its acquisition of Evidera in September 2016. In May of this year, the CRO combined its medical affairs research operations (MARO) team and Evidera to create a dedicated real-world research and market access unit.
Margaret Vernon, vice president and general manager of the patient-centered research team at Evidera explained the expansion moves the company’s service offerings beyond its “traditional core competency” of clinical outcome assessment (COA) and patient-reported outcome (PRO) development.
The company will now provide study types including patient preference, patient experience, and other patient engagement research offerings and consulting, she said.
“We have been developing expertise and delivery models for these services and our intent is to aggressively grow our expertise and capabilities in these areas over time to fulfill new evidence requirements under the 21st Century Cures act and FDA’s patient-focused drug development mandate,” Vernon told Outsourcing-Pharma.com.
“This new, focused structure improves and expands our capabilities and breadth of services, which allows us to better support our clients as they undertake patient-focused drug development initiatives,” she added.
Vernon said Evidera will also leverage PPD’s patient recruitment and retention capabilities in clinical studies to help align pre- and post-market research.
“Perhaps most important, the focus of all of our patient-centered research is to empower patients by giving them more options, greater involvement in research, and faster access to treatments and potential cures,” she added.
“Advancing the field of patient-centered research will enable the introduction of better treatments that are faster to market, and better aligned with the needs and wants of patients.”